Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014 (2014), Article ID 260939, 6 pages
http://dx.doi.org/10.1155/2014/260939
Clinical Study

Long-Term and Short-Term Effects of Hemodialysis on Liver Function Evaluated Using the Galactose Single-Point Test

1Department of Internal Medicine, Cardinal Tien Hospital, School of Medicine, Fu-Jen Catholic University, 362 Chung-Cheng Road, Hsin-Tien District, New Taipei City 23148, Taiwan
2Department of Internal Medicine, Cardinal Tien Hospital, Yonghe Branch, New Taipei City 23445, Taiwan
3Department of Pediatrics, Taoyuan Armed Forces General Hospital, Taoyuan 325, Taiwan
4Division of Internal Medicine, Chang-Gang Memorial Hospital, Taoyuan, No. 5 Fusing Street, Gueishan, Taoyuan County 333, Taiwan
5Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, No. 161 Section 6 Minquan East Road, Neihu District, Taipei City 114, Taiwan
6School of Pharmacy, National Defense Medical Center, No. 161 Section 6 Minquan East Road, Neihu District, Taipei City 114, Taiwan

Received 27 March 2014; Revised 15 June 2014; Accepted 18 June 2014; Published 10 July 2014

Academic Editor: Luis A. Videla

Copyright © 2014 Yi-Chou Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Boone, D. Meyer, P. Cusick et al., “Selection and interpretation of clinical pathology indicators of hepatic injury in preclinical studies,” Veterinary Clinical Pathology, vol. 34, no. 3, pp. 182–188, 2005. View at Google Scholar · View at Scopus
  2. G. A. Cohen, J. A. Goffinet, R. K. Donabedian, and H. O. Conn, “Observations on decreased serum glutamic oxalacetic transaminase (SGOT) activity in azotemic patients,” Annals of Internal Medicine, vol. 84, no. 3, pp. 275–280, 1976. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Guh, Y. Lai, C. Yang et al., “Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients,” Nephron, vol. 69, no. 4, pp. 459–465, 1995. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Leblanc, L. F. Roy, J. Villeneuve, B. Malo, G. Pomier-Layrargues, and L. Legault, “Liver blood flow in chronic hemodialysis patients,” Nephron, vol. 73, no. 3, pp. 396–402, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Keiding, P. B. Andreasen, and L. Fauerholdt, “Effect of phenobarbital induction on galactose elimination capacity in the rat,” Biochemical Pharmacology, vol. 22, no. 18, pp. 2293–2297, 1973. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Keiding, S. Johansen, K. Winkler, K. Tonnesen, and N. Tygstrup, “Michaelis Menten kinetics of galactose elimination by the isolated perfused pig liver,” American Journal of Physiology, vol. 230, no. 5, pp. 1302–1313, 1976. View at Google Scholar · View at Scopus
  7. T. H. Young, H. S. Tang, Y. C. Chao et al., “Quantitative rat liver function test by galactose single point method,” Laboratory Animals, vol. 42, no. 4, pp. 495–504, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Becker, “13C breath tests for measurement of liver function,” Gut, vol. 43, supplement 3, pp. S25–S27, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. Food and Drug Agency and Center for Drug Evaluation and Research (CDER), Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling, Guidance for Industry, U.S. Department of Health and Human Services, 2003.
  10. H. Tang and O. Y. Hu, “Assessment of liver function using a novel galactose single point method,” Digestion, vol. 52, no. 3-4, pp. 222–231, 1992. View at Publisher · View at Google Scholar · View at Scopus
  11. O. Yoa-Pu Hu, H.-S. Tang, and C. Chang, “The influence of chronic lobular hepatitis on pharmacokinetics of cefoperazone novel galactose single-point method as a measure of residual liver function,” Biopharmaceutics and Drug Disposition, vol. 15, no. 7, pp. 563–576, 1994. View at Publisher · View at Google Scholar · View at Scopus
  12. J. T. Daugirdas and D. Schneditz, “Overestimation of hemodialysis dose depends on dialysis efficiency by regional blood flow but not by conventional two pool urea kinetic analysis,” ASAIO Journal, vol. 41, no. 3, pp. M719–M724, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Y.-. Hu, H.-. Tang, and C.-. Chang, “Novel galactose single point method as a measure of residual liver function: example of cefoperazone kinetics in patients with liver cirrhosis,” Journal of Clinical Pharmacology, vol. 35, no. 3, pp. 250–258, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. Centers for Disease Control (CDC), M.o.H.a.W., R.O.C. (Taiwan), Statistics of Communicable Diseases and Surveillance Report, 2012.
  15. The National Kidney Function Kidney Disease Outcome Quality Initative (NKF/KDOQI), Clinical Practice Guidelines and Clinical Practice Recommendations, 2006.
  16. S. Keiding, H. Vilstrup, and L. Hansen, “Importance of flow and haematocrit for metabolic function of perfused rat liver,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 40, no. 4, pp. 355–359, 1980. View at Publisher · View at Google Scholar · View at Scopus
  17. S. S. Hanna, “Measurement of liver blood flow by galactose clearance,” Canadian Journal of Surgery, vol. 27, no. 3, pp. 218–220, 1984. View at Google Scholar · View at Scopus
  18. R. Schlichtig, D. J. Kramer, and M. R. Pinsky, “Flow redistribution during progressive hemorrhage is a determinant of critical O2 delivery,” Journal of Applied Physiology, vol. 70, no. 1, pp. 169–178, 1991. View at Google Scholar · View at Scopus
  19. P. M. Reilly, K. B. Wilkins, K. C. Fuh, U. Haglund, and G. B. Bulkley, “The mesenteric hemodynamic response to circulatory shock: an overview,” Shock, vol. 15, no. 5, pp. 329–343, 2001. View at Publisher · View at Google Scholar · View at Scopus
  20. W. W. Lautt, “Mechanism and role of intrinsic regulation of hepatic arterial blood flow: hepatic arterial buffer response,” The American Journal of Physiology, vol. 249, no. 5, pp. G549–G556, 1985. View at Google Scholar · View at Scopus
  21. T. Kishimoto, K. Sugimura, T. Nakatani et al., “The effects of diffusion and ultrafiltration on cardiac output and organ blood flows,” Proceedings of the European Dialysis and Transplant Association, vol. 19, pp. 275–280, 1983. View at Google Scholar · View at Scopus
  22. S. M. Jakob, E. Ruokonen, O. Vuolteenaho, E. Lampainen, and J. Takala, “Splanchnic perfusion during hemodialysis: evidence for marginal tissue perfusion,” Critical Care Medicine, vol. 29, no. 7, pp. 1393–1398, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Queckenberg and U. Fuhr, “Influence of posture on pharmacokinetics,” European Journal of Clinical Pharmacology, vol. 65, no. 2, pp. 109–119, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. T. Gallagher and M. Lyon, “Molecular structure of heparan sulfate and interactions with growth factors and morphogens,” in Proteoglycans: Structure, Biology And Molecular Interactions, M. V. Iozzo, Ed., pp. 27–59, Marcel Dekker, New York, NY, USA, 2000. View at Google Scholar
  25. G. Shiota, T. C. Wang, T. Nakamura, and E. V. Schmidt, “Hepatocyte growth factor in transgenic mice: effects on hepatocyte growth, liver regeneration and gene expression,” Hepatology, vol. 19, no. 4, pp. 962–972, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. G. Shiota, J. Okano, H. Kawasaki, T. Kawamoto, and T. Nakamura, “Serum hepatocyte growth factor levels in liver diseases: clinical implications,” Hepatology, vol. 21, no. 1, pp. 106–112, 1995. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Rampino, C. Libetta, W. de Simone et al., “Hemodialysis stimulates hepatocyte growth factor release,” Kidney International, vol. 53, no. 5, pp. 1382–1388, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Borawski and M. Myśliwiec, “Serum hepatocyte growth factor is associated with viral hepatitis, cardiovascular disease, erythropoietin treatment, and type of heparin in haemodialysis patients,” Nephrology Dialysis Transplantation, vol. 17, no. 4, pp. 637–644, 2002. View at Google Scholar · View at Scopus
  29. C. R. Hiley, M. S. Yates, P. J. Roberts, and A. E. Bloom, “Alterations in liver blood flow during glycerol-induced acute renal failure in the rat,” Nephron, vol. 26, no. 5, pp. 244–248, 1980. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Sørensen, K. S. Mikkelsen, K. Frisch, L. Bass, B. M. Bibby, and S. Keiding, “Hepatic galactose metabolism quantified in humans using 2-18F-fluoro-2-deoxy-D-galactose PET/CT,” Journal of Nuclear Medicine, vol. 52, no. 10, pp. 1566–1572, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. S. G. Ahn, T. J. Jeon, S. D. Lee et al., “A survival benefit of major hepatectomy for hepatocellular carcinoma identified by preoperative [18F] fluorodeoxyglucose positron emission tomography in patients with well-preserved hepatic function,” European Journal of Surgical Oncology, vol. 39, no. 9, pp. 964–973, 2013. View at Publisher · View at Google Scholar · View at Scopus